28. Aug 2026
Description
(AWP Alliance News) - The following stocks are the leading risers and fallers in Europe's major stock indices on Friday.
----------
CAC 40 winners
----------
Hermes International SCA, up 4.0% at EUR1,624.75, luxury-goods stocks rise across Europe
Legrand SA, up 3.2% at EUR140.25
EssilorLuxottica SA, up 3.1% at EUR162.30, launches share buyback of up to 5 million shares
----------
CAC 40 losers
----------
Orange SA, down 0.7% at EUR14.93
Capgemini SE, down 0.6% at EUR109.08
Pernod Ricard SA, down 0.5% at EUR64.36
----------
DAX 40 winners
----------
RWE AG, up 2.6% at EUR59.00, broker Berenberg ups price target to EUR72
BMW AG, up 2.0% at EUR61.10
Brenntag SE, up 1.9% at EUR61.55, announces distribution agreement with Zeus Hygia
----------
DAX 40 losers
----------
Puma SE, down 2.1% at EUR25.59
Qiagen NV, down 1.2% at EUR37.31, launches QIAsymphony Connect nucleic acid extraction platform
SAP SE, down 0.9% at EUR188.75
----------
FTSE 100 winners
----------
SSE PLC, up 1.9% at 2,427.00p
Melrose Industries PLC, up 1.8% at 518.20p
Croda International PLC, up 1.8% at 3,489.50p
----------
FTSE 100 losers
----------
Kingfisher PLC, down 1.7% at 312.80p
Sage Group PLC, down 1.7% at 1,084.50p
Autotrader Group PLC, down 1.4% at 528.80p
----------
MIB 40 winners
----------
Moncler Spa, up 2.0% at EUR48.14, luxury-goods stocks rise across Europe
Tenaris SA, up 1.8% at EUR23.51
Brunello Cucinelli Spa, up 1.6% at EUR89.28
----------
MIB 40 losers
----------
Leonardo Spa, down 1.6% at EUR54.19
DiaSorin Spa, down 0.3% at EUR76.64
Fincantieri Spa, down 0.3% at EUR12.70
----------
SMI 20 winners
----------
Compagnie Financiere Richemont SA, up 1.8% at CHF194.60, tracks luxury stocks higher
Givaudan SA, up 1.8% at CHF3,321.50
Kuehne & Nagel International AG, up 1.6% at CHF219.80
----------
SMI 20 losers
----------
Alcon AG, down 1.4% at CHF57.75
Logitech International SA, down 0.9% at CHF78.69
Lonza Group AG, down 0.4% at CHF586.70
----------
European stock movers in focus:
----------
EssilorLuxottica SA, up 3.1% at EUR162.30, 12-month range EUR159.15-EUR323.80. Launches a share buyback programme covering up to 5 million shares, citing confidence in the group's value creation and long-term prospects. Grants a mandate to an unnamed investment services provider to begin purchases on Friday, depending on market conditions. The programme is being carried out under the authorisation approved by shareholders at EssilorLuxottica's annual general meeting in April.
----------
Qiagen NV, down 1.2% at EUR37.31, 12-month range EUR27.87-EUR48.80. Launches QIAsymphony Connect, an automated clinical nucleic acid extraction platform designed to help laboratories standardise extraction across diverse assay workflows. The platform builds on more than 3,300 cumulative global placements of QIAsymphony and supports applications including liquid biopsy, oncology and infectious disease diagnostics. Qiagen says it has already received initial customer orders, indicating early adoption as the platform enters broader commercial availability.
----------
Brenntag SE, up 1.9% at EUR61.55, 12-month range EUR43.72-EUR66.86. Announces exclusive distribution agreement with Zeus Hygia Life Sciences Pvt Ltd. Zeus Hygia is a Hyderabad, India-based health ingredients company which Brenntag describes as "one of the fastest growing nutraceutical ingredient companies globally and a science-led ingredient innovator." The Essen, Germany-based chemical company says the partnership agreement covers ingredients and formulations for metabolic health and glucose management, cognitive wellness, menopausal health and anti-inflammatory support. The company will act as the sole authorised distributor of Zeus Hygia's products across Eastern Europe.
----------
Bayer AG, up 1.1% at EUR48.99, 12-month range EUR25.78-EUR53.92. Applies for extended use of the drug Kerendia in Japan for chronic kidney disease. Bayer says the application is supported by positive phase three results in adults with non-diabetic CKD. The company says Kerendia blocks the effects of mineralocorticoid receptor overactivation, which can help to prevent CKD progression and cardiovascular damage.
----------
By Eva Castanedo, Alliance News senior economics reporter
Comments and questions to newsroom [at] alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.
